SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) July 9, 1998
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
<PAGE>
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today that
pursuant to a request from its European distributor,
EuroSurgical Ltd., Diasensor(R) 1000s have been shipped
to the UK. This initial UK shipment will kick off the
sales & distribution of the world's first non-invasive
glucose sensor approved for market sales.
George Cranstone, director of EuroSurgical, said
that interest is quite high for the Diasensor and
confirmed that the market for diabetic products is
large in the EU as there are approximately 30 million
people with diabetes.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired
Not Applicable.
(b) Pro Forma Financial Information
Not Applicable.
(c) Exhibits - Press Release.
<PAGE>
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
DATED: July 9, 1998 Fred E. Cooper, CEO
BICO
<PAGE>
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
For More Information, Call:
Investors Media
Diane McQuaide
Susan Taylor
1.412.429.0673 phone
1.412.279.9455 phone
1.412.279.9690 fax
1.412.279.9447 fax
BIOCONTROL SHIPS DIASENSORS TO THE UK
Pittsburgh, PA - July 9, 1998 - Biocontrol Technology, Inc.
(Nasdaq:BICO) announced today that pursuant to a request from its
European distributor, EuroSurgical Ltd., Diasensor(R)1000s have
been shipped to the UK. This initial UK shipment will kick off
the sales & distribution of the world's first non-invasive
glucose sensor approved for market sales.
Biocontrol learned late last week that it had been granted
approval by its Notified Body, TUV Rheinland Product Safety GmbH,
Cologne, Germany, to apply the CE Mark to its noninvasive glucose
sensor. This allowed Biocontrol to begin shipments into the
European Union (EU) and to market the noninvasive glucose sensor
for diabetics almost anywhere outside of the US.
George Cranstone, director of EuroSurgical, said that
interest is quite high for the Diasensor and confirmed that the
market for diabetic products is large in the EU as there are
approximately 30 million people with diabetes. EuroSurgical and
Biocontrol are implementing a plan for marketing the Diasensor in
the UK, including physician training on the use of the device.
Although Biocontrol's initial marketing efforts will be
concentrated in the UK, other countries that have expressed an
interest in the Diasensor, but were awaiting the European
marketing approval, will also be pursued.
Biocontrol Technology, Inc. (www.bico.com) has its corporate
offices in Pittsburgh, PA and is involved in the development and
manufacture of biomedical devices and environmental products.
